Life Sciences & Healthcare Innovation Hub
Cooley Rx
Cooley Rx is a virtual series focused on the life sciences and healthcare sectors. Join us as we discuss the top issues and trends in these industries – and provide decision-makers with information they can use to strengthen their organizations.
Upcoming webinar
Life Sciences Litigation: Clinical Trials and Tribulations – Prosecution and Litigation Implications of Clinical Trial IP and Prior Art
Cooley partners Jon Cousin and Jon Davies will discuss the following:
- What types of patentable subject matter, filing timelines and strategies should companies consider?
- What prior art issues should companies be aware of?
- What are the consequences of protocols as prior art?
View on demand
Life Sciences Litigation: IP Diligence – The Submarine Deal Killer (Practical Approaches and Strategic Lessons to Avoid Common Pitfalls)
Cooley patent counseling and prosecution partner Mika Mayer and IP litigation partner Chad Shear discussed how to avoid common IP diligence pitfalls and ensure your deals run smoothly.
Life Sciences Litigation: The Demise of Chevron Deference, Its Impact on the Regulatory and Patent Frameworks Surrounding Hatch-Waxman, and the Rising Tide of Litigation Sure to Follow
FDA insider and head of Cooley’s global life sciences and healthcare regulatory practice, Sonia Nath, and Chad Shear, a Hatch-Waxman litigator with more than 25 years of experience discussed the implications of the demise of the Chevron doctrine and how to put your company in the best position to thrive.
Life Sciences Litigation: Biosimilars, 2024 Year in Review
The past year brought many significant developments in the landscape for biosimilars litigation. Cooley lawyers Brianna Patterson and Geoff Biegler recapped the most important biosimilar cases, decisions, industry developments and government initiatives from the past year. The discussion included an overview of 2024’s biosimilar approvals, biosimilar-related litigations and post-grant proceedings, as well as what to watch for in 2025.
Life Sciences Litigation: Hatch-Waxman, 2024 Year in Review
Cooley life sciences intellectual property litigation partners Geoff Biegler and Betsy Flanagan and associate Bonnie Fletcher Price discussed need-to-know case outcomes, legal developments and government initiatives from the past year that impact Hatch-Waxman litigants in both the courtroom and the boardroom.
Life Sciences Litigation: IPRs, Preliminary Injunctions and Trials
This virtual event provided an in-depth look at how inter partes review (IPR) proceedings impact parallel district court litigation, including how these proceedings come into evidence during preliminary injunctions (PIs) and trials, and how the pendency of IPRs can affect PI and trial outcomes, particularly in life sciences patent litigation.
Life Sciences Litigation: 505(b)(2) Applications and Beyond: Prosecution and Litigation Strategies for Filing and Defending Against 505(b)(2) NDAs
In this webinar, Cooley attorneys Sanya Sukduang, Jon Cousin and Jason Valentine explore strategies from a prosecution and litigation perspective, providing insight on how to evaluate freedom to operate for a 505(b)(2) product, develop a patent portfolio and exclusivity strategy for 505(b)(2) products that protects against generics and subsequent 505(b)(2) filers.
Life Sciences Litigation: Planning for the Future: Aligning Prosecution and Litigation Strategies
In this webinar, Cooley life sciences intellectual property litigation partner Chad Shear and life sciences patent partner Jon Cousin discussed common pitfalls in patent drafting and prosecution that are exploited during litigation, structuring patent portfolio to align with development milestones, clinical trials and product approval and drafting strong and focused patent applications while avoiding unnecessary disclosure that can render future invention obvious.
Life Sciences & ESG: Key Considerations and Developments
Join Cooley’s life sciences and ESG teams – including lawyers Beth Sasfai, Michael Mencher, Div Gupta and Megan Taing – as they discuss how and when ESG - environmental, social and governance - issues become relevant to growth-stage companies, unique issues for life sciences ESG strategy, recent trends in life sciences ESG activity, the role of customers, investors and other stakeholders, how industry companies are responding to recent Securities and Exchange Commission, California and EU regulations, and the impact of EU trends and regulations on US companies.
Life Sciences Litigation: Patent Litigation Damages Strategies, Trends and Legal Developments
Cooley life sciences litigation partners Betsy Flanagan and Orion Armon discussed recent trends in life sciences damages awards, drivers behind large damages awards, important developments in the law, and prevalence and availability of injunctive relief.
Life Sciences Litigation: Preparing for Successful Hatch-Waxman Litigation
Obtaining favorable results in Hatch-Waxman litigation is critical for branded drug companies. Join Cooley life sciences litigation partners Chad Shear and Geoff Biegler as they discuss strategies for branded companies to best position themselves for success in Hatch-Waxman litigation. Leveraging 40+ years of combined experience in abbreviated new drug application (ANDA) cases, Chad and Geoff will walk through when you should prepare for Hatch-Waxman litigation, what steps you should take and how to avoid common pitfalls.
Navigating Regulatory Risks in Mergers and Acquisitions: Trends and Insights for Dealmakers
During this webinar, the speakers will share valuable insights to help you successfully navigate regulatory hurdles, provide practical tips for M&A negotiations, and highlight provisions that have been used to manage the heightened regulatory risks associated with deals.
Life Sciences Litigation: Considerations for the US Inflation Reduction Act and Expanded March-In Rights
In 2024, the US Centers for Medicare & Medicaid Services will release the maximum fair price for the first 10 drugs selected for the Medicare Drug Price Negotiation Program created under the Inflation Reduction Act (IRA). In addition, the National Institute of Standards and Technology will release guidance – including the use of price – for exercising march-in rights under the Bayh-Dole Act. In this webinar, Chad Shear, experienced Cooley life sciences patent trial lawyer, and Vince Sampson, who leads the firm’s public policy practice, will discuss the process and impacts of the IRA’s drug pricing program – and what expanded march-in rights could mean for federally funded life science research.
Life Sciences Litigation: Implications and Perspectives on the FTC’s Recent Orange Book Statements and Disputes
Following the Federal Trade Commission’s September 2023 policy statement, the FTC initiated Orange Book patent listing disputes against 10 companies’ pharmaceutical products. During this presentation, intellectual property litigation partner Jon Davies and antitrust special counsel David Burns will discuss the backdrop for these drug device patent listing disputes and the implications of the FTC’s recent related policy statements.
Understanding Washington’s My Health My Data (MHMD) Act: Applicability, Scope and Requirements
The Washington My Health My Data (MHMD) Act is arguably one of the most stringent privacy laws in the US, and it further complicates the already byzantine US patchwork approach to privacy. While the MHMD Act purports to focus on healthcare-related data and close the “gap” that exists for entities not governed by the Health Information Portability and Accountability Act (HIPAA), it applies on a much wider basis to more data, as well as to organizations whose core business may have nothing to do with healthcare.
Life Sciences Litigation: Hatch-Waxman, 2023 Year in Review
Cooley lawyers Geoff Biegler, Betsy Flanagan and Bonnie Fletcher Price gave a recap of Hatch-Waxman litigation in 2023 and a look forward to 2024. In this session, Geoff, Betsy and Bonnie discussed the need-to-know case outcomes, legal developments, and government initiatives from the past year impacting Hatch-Waxman litigants in both the courtroom and the boardroom. This program is designed for in-house lawyers and executives interested in the latest topics and trends in Hatch-Waxman litigation, whether they are new to the field or have decades of experience.
Life Sciences Litigation: Biosimilars, 2023 Year in Review
Over the past year, the landscape for biosimilars litigation has continued to evolve, as the field moves into a new wave of products and cases. Cooley lawyers Brianna Patterson, Geoff Biegler and Michelle Rhyu recapped the most important cases, decisions and industry developments from the past year, as well as new strategy considerations gleaned from those developments – both from the reference product sponsor and biosimilar applicant perspectives. The discussion also included an overview of 2023’s biosimilar approvals, biosimilar-related post-grant proceedings and a discussion of what to watch for in 2024.
Life Sciences Litigation: Tracking the Paths of Regulatory and Patent Law During Drug Development
From the inception of a drug through approval, there are any number of inflection points that have significance from either a regulatory or patent perspective. Often, decisions that are made at those points have long-lasting implications. Join Sonia Nath, chair of Cooley’s global life sciences and healthcare regulatory practice group, and Chad Shear, experienced life sciences patent trial lawyer, as they explore those inflection points.
Life Sciences Litigation: Learnings from 40 Years of Litigation Under the Hatch-Waxman Act
We are approaching the 40-year anniversary of the Hatch-Waxman Act – the comprehensive legal framework governing pharmaceutical industry innovation, patent terms and price competition. Please join members of Cooley’s life sciences litigation team as they explore the origins and application of the act, as well as where the law is headed as it turns 40. This program is designed for in-house lawyers and pharmaceutical industry executives who are new to the act, along with those who have been working with it for some time.
A CREATES Act Primer
Since its enactment in late 2019, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act has provided certain eligible drug developers with a private right of action to sue branded reference drug companies that fail to provide samples of their products to support abbreviated drug applications. Join Cooley as we provide an overview of the CREATES Act, discuss its implications and highlight issues to consider in responding to a CREATES Act request.
An Ounce of Prevention – Proactive Planning for Healthcare and Life Sciences Companies
Even the best-laid plans need contingency options. In this presentation, we share the top five things a life sciences company should be thinking about in the current environment, as well as insight from recent deals and litigation experiences.
Building Technology Platforms Through Discovery Collaborations
Companies with platform technologies that have broad applicability can often benefit from early discovery collaborations with pharma companies in certain therapeutic areas or on particular targets. These discovery collaborations can validate and improve the platform, provide research and development funding, and diversify the company’s economic interest beyond its internal programs. Join Cooley as we dive into some of the most common structures and pitfalls for discovery collaborations.
Patent Claiming Strategies Do’s and Don’ts
Patents give companies exclusive rights in their inventions – and when a competitor is encroaching on your market share, you can use your patents to stop them, although the outcome will depend on the strength of the patent claims. This session discusses claiming strategies from a litigation perspective. We provide the do’s and don’ts of claim drafting, so you can ensure your patent claims are strong, defensible and able to withstand scrutiny in litigation.
Life Sciences Dealmaking: Recent Trends and the Outlook for 2023
This session provided a review of life sciences dealmaking trends over the past volatile year, including deal points to watch and predictions for the 2023 M&A landscape in this fast-moving sector.
Biotech + Breaking Glass: Leading Women in Life Sciences
Cooley’s Biotech + Breaking Glass: Leading Women in Life Sciences series features women in the life sciences industry sharing and celebrating their stories, obstacles and milestones.
Preparing for and Winning Medical Device Patent Litigation
Cooley intellectual property litigators provide guidance to help your company prepare for and prevail in patent litigation in the medical device and diagnostics field. This session focuses on best practices for offensive and defensive litigation matters, as well as ways to navigate transactions during pending litigation.
Same Game, New (and More of the Same) Targets: How Government Enforcers Are Focusing on Healthcare and the Life Sciences
Cooley partners break down the top government enforcement trends and provide thoughtful insight into hotbed enforcement issues.
What’s Going On in Washington? Legislative and Enforcement Updates in the Healthcare and Life Sciences Industry
Cooley’s Food and Drug Administration and legislative experts share information about FDA enforcement trends in the life sciences space – including legislative activity that life sciences and healthcare companies should know about.
Preparing to Go Public: Key Considerations for Life Sciences + Healthcare Companies
Cooley lawyers discuss key factors that life sciences and healthcare companies should consider as they prepare to go public in the US.
Digital Health Investment Trends & 2022 Outlook
Leading venture capitalists share their investment outlook and relay advice to entrepreneurs who are fundraising.
Launch Strong: Strategies for Enforcing and Protecting Brands Prior to Commercialization
This presentation covers tools and cost-effective strategies for enforcing and strengthening potential trademarks prior to product launch.
Life Sciences in the Antitrust Hot Seat – Trends and Guidance
Cooley antitrust thought leaders discuss key trends and strategies for navigating the changing enforcement landscape.
COVID + Life Sciences Industry: Impact and Response
Industry leaders and Cooley partners explore how COVID-19 impacted the life sciences industry, how companies quickly and swiftly responded, and what this could mean for the industry moving forward.
D&O Trends in 2021: Hard Market, COVID-19 and Other Factors Impacting Life Science Companies
Cooley partners discuss the trends that may have had significant risk implications for senior management in 2021 and beyond.
Productwise – Liability in Times of Change for the Life Sciences Industry – Part One
In the first part of this two-part virtual series, Cooley’s international products team explores liability changes within the life sciences industry and identifies the risks and challenges involved.
Productwise – Liability in Times of Change for the Life Sciences Industry – Part Two
In the second part of this two-part virtual series, Cooley’s international products team examines significant liability risks for life sciences companies in the next five to 10 years, including the changing liability landscape, as well as risks in the context of emerging technologies.
IP Basics and Portfolio Strategies for the Pharmaceutical and Biotech Industry
Cooley intellectual property professionals explain foundational concepts for developing robust and cost-effective patent portfolios in various typical product development and life cycle management scenarios.
Four New Years – Life Science Policy in the Biden-Harris Era
Cooley lawyers discuss the key issues, priorities, and people shaping the life sciences policy and regulatory landscape in Washington, DC, including information relevant to life science companies at all states of development, as well as investors.
Biosimilars: Lessons Learned 10 Years After Enactment of the Biologics Price Competition and Innovation Act (BPCIA)
Cooley partners are among the speakers offering a recap of the key provisions of the BPCIA statute and an explanation of biosimilars’ path to the marketplace.
Hatch-Waxman 101 for the Emerging Life Science Company
Cooley partners discuss considerations for innovative life science companies that have filed, or will soon file, new drug applications or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation.
More information
Please email Amanda Richardson for more information or if you have any questions about the Cooley Rx series.
Four Decades Driving Innovation in Healthcare and Life Sciences
Cooley is a global leader in the industry
Cooley Rx
A virtual series focused on the life sciences and healthcare sectors
In the Moment + Up to Date
Join our list to receive updates when new content of interest to life sciences and healthcare leaders is released
Group contacts
